Emergent BioSolutions (EBS) EBT Margin (2011 - 2026)

Emergent BioSolutions' EBT Margin history runs 16 years deep, the most recent figure standing at 8.58% for Q1 2026.

• On a quarterly basis, EBT Margin fell 3313.0% year-over-year to 8.58% in Q1 2026; TTM through Mar 2026 was 0.52%, a 871.0% increase from a year earlier, with the FY2025 full-year figure at 11.15%, up 2484.0% from the prior year.
• EBT Margin improved to 8.58% in Q1 2026 per EBS's latest filing, from 34.1% in the prior quarter.
• Across five years, EBT Margin topped out at 48.47% in Q3 2024 and bottomed at 539.6% in Q2 2024.
• The 5-year median for EBT Margin is 18.59% (2022), against an average of 49.64%.
• Across the five-year window, EBT Margin plunged 46555 bps in 2024 and soared 52768 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 18.59% in 2022, then slipped by 6 bps to 19.7% in 2023, then gained by 28 bps to 14.18% in 2024, then tumbled by 141 bps to 34.1% in 2025, then soared by 125 bps to 8.58% in 2026.
• Per Business Quant, the three latest EBS EBT Margin figures stand at 8.58% (Q1 2026), 34.1% (Q4 2025), and 24.92% (Q3 2025).